Contineum Therapeutics (CTNM) Competitors $13.65 +0.35 (+2.63%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CTNM vs. DAWN, TVTX, PRAX, SAVA, SNDX, SPRY, RCUS, KURA, MESO, and GYREShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Day One Biopharmaceuticals (DAWN), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Cassava Sciences (SAVA), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), Arcus Biosciences (RCUS), Kura Oncology (KURA), Mesoblast (MESO), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Day One Biopharmaceuticals Travere Therapeutics Praxis Precision Medicines Cassava Sciences Syndax Pharmaceuticals ARS Pharmaceuticals Arcus Biosciences Kura Oncology Mesoblast Gyre Therapeutics Contineum Therapeutics (NASDAQ:CTNM) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, community ranking, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media prefer CTNM or DAWN? In the previous week, Day One Biopharmaceuticals had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for Day One Biopharmaceuticals and 2 mentions for Contineum Therapeutics. Day One Biopharmaceuticals' average media sentiment score of 1.21 beat Contineum Therapeutics' score of 0.03 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Day One Biopharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CTNM or DAWN? Contineum Therapeutics presently has a consensus price target of $29.25, suggesting a potential upside of 114.29%. Day One Biopharmaceuticals has a consensus price target of $35.71, suggesting a potential upside of 162.22%. Given Day One Biopharmaceuticals' higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Day One Biopharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, CTNM or DAWN? Contineum Therapeutics has higher revenue and earnings than Day One Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M7.04$22.72MN/AN/ADay One BiopharmaceuticalsN/AN/A-$188.92M-$1.03-13.22 Do insiders and institutionals hold more shares of CTNM or DAWN? 88.0% of Day One Biopharmaceuticals shares are held by institutional investors. 8.4% of Day One Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CTNM or DAWN more profitable? Day One Biopharmaceuticals' return on equity of -22.40% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% Day One Biopharmaceuticals N/A -22.40%-19.79% Does the MarketBeat Community favor CTNM or DAWN? Day One Biopharmaceuticals received 38 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 66.18% of users gave Day One Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesDay One BiopharmaceuticalsOutperform Votes4566.18% Underperform Votes2333.82% SummaryDay One Biopharmaceuticals beats Contineum Therapeutics on 9 of the 13 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$342.85M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E RatioN/A4.8389.0213.30Price / Sales7.04372.991,207.2881.01Price / Cash10.6952.2739.1736.03Price / Book1.677.876.085.74Net Income$22.72M$153.61M$119.07M$225.93M7 Day Performance-24.79%-2.00%-1.84%-1.32%1 Month Performance-15.06%-7.47%-3.65%0.60%1 Year PerformanceN/A31.80%31.62%26.23% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics1.6382 of 5 stars$13.65+2.6%$29.25+114.3%N/A$342.85M$50M0.0031DAWNDay One Biopharmaceuticals1.9859 of 5 stars$13.62+0.7%$35.71+162.2%+12.4%$1.36BN/A0.0060Positive NewsTVTXTravere Therapeutics2.9019 of 5 stars$17.86+2.7%$22.62+26.6%+210.6%$1.36B$145.24M0.00460PRAXPraxis Precision Medicines1.754 of 5 stars$73.68+1.3%$146.33+98.6%+299.3%$1.36B$2.45M0.00110SAVACassava Sciences3.9767 of 5 stars$26.05-7.0%$111.50+328.0%+59.6%$1.35BN/A0.0030SNDXSyndax Pharmaceuticals4.0038 of 5 stars$15.95+1.1%$37.18+133.1%+3.4%$1.35B$139.71M0.00110Analyst ForecastAnalyst RevisionSPRYARS Pharmaceuticals2.734 of 5 stars$13.55-1.7%$24.00+77.1%+183.5%$1.34B$30,000.000.0090Analyst RevisionRCUSArcus Biosciences2.677 of 5 stars$14.62+0.8%$34.00+132.6%+4.7%$1.33B$117M0.00500KURAKura Oncology4.082 of 5 stars$15.91-0.3%$28.83+81.2%+66.6%$1.24BN/A0.00142Analyst ForecastMESOMesoblast1.3555 of 5 stars$10.33-4.5%$11.50+11.3%+345.3%$1.24B$5.90M0.0080Gap DownGYREGyre Therapeutics0.4932 of 5 stars$12.91-0.1%N/A-12.1%$1.21B$113.45M0.0040 Related Companies and Tools Related Companies DAWN Competitors TVTX Competitors PRAX Competitors SAVA Competitors SNDX Competitors SPRY Competitors RCUS Competitors KURA Competitors MESO Competitors GYRE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTNM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
